Abbott Laboratories has experienced fluctuating revenue due to the pandemic, but its diabetes care segment, especially the FreeStyle Libre CGM devices, has shown consistent growth. With new products like Libre Rio and Lingo, Abbott aims to reach $10 billion in annual sales by 2028.